Can febuxostat and fenofibrate be taken together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, febuxostat and fenofibrate can be taken together safely

Febuxostat and fenofibrate can be co-administered without significant drug-drug interactions, and this combination may actually provide therapeutic benefits for patients with both gout and dyslipidemia. Multiple guidelines explicitly support this approach, and there are no contraindications to concurrent use.

Evidence Supporting Concurrent Use

Guideline Recommendations

The 2012 American College of Rheumatology guidelines explicitly recommend fenofibrate as part of a comprehensive urate-lowering therapy (ULT) strategy 1. Specifically, they state that "agents other than probenecid with clinically significant uricosuric effects, such as fenofibrate and losartan, can be therapeutically useful as components of a comprehensive ULT strategy" and that "effective therapeutic options include addition of a uricosuric agent (eg, probenecid, fenofibrate, or losartan) to an XOI drug" 1.

The 2016 EULAR guidelines for gout management recommend that when gout occurs in a patient with hyperlipidemia, clinicians should consider fenofibrate 2. This directly addresses the clinical scenario where both medications would be used together.

No Drug-Drug Interactions

The 2026 ACC/AHA dyslipidemia guidelines note that fenofibrate can be used in combination with statins with monitoring, but make no mention of interactions with febuxostat 3. The 2026 kinase inhibitor-associated hyperlipidemia guidelines explicitly state "No known interactions" for fenofibrate with other drug classes 4.

Complementary Mechanisms

  • Febuxostat works as a xanthine oxidase inhibitor to lower uric acid production
  • Fenofibrate has uricosuric properties (helps kidneys excrete uric acid) in addition to its lipid-lowering effects 5

Research demonstrates that fenofibrate actually provides additional uric acid lowering when combined with xanthine oxidase inhibitors like febuxostat 5. In a study of 863 gout patients, those taking fenofibrate with allopurinol or febuxostat had significantly greater reductions in serum uric acid levels (-2.40 ± 2.28 mg/dL) compared to xanthine oxidase inhibitors alone (-1.81 ± 2.41 mg/dL, p = 0.043) 5.

Monitoring Considerations

While the combination is safe, monitor for:

  • Renal function: Both drugs require dose adjustment in renal impairment. Fenofibrate can reversibly elevate serum creatinine 3, and febuxostat dosing should be adjusted based on creatinine clearance 2
  • Liver enzymes: Both medications can affect hepatic transaminases 3, 1
  • Serum uric acid levels: To ensure therapeutic targets are being met (typically <6 mg/dL) 2

Important Caveats

Do not confuse fenofibrate with gemfibrozil - gemfibrozil should NOT be combined with statins due to increased risk of rhabdomyolysis 3, 6, but this restriction does not apply to febuxostat. Fenofibrate is the preferred fibrate when combination therapy is needed 6.

The combination is particularly rational for patients with both gout and hypertriglyceridemia, as fenofibrate addresses both conditions simultaneously through its lipid-lowering and uricosuric effects 5, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.